Company / Total Debt
SUTRO BIOPHARMA, INC. Total Debt History
FY2018-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$16.3M
FY2022
5-year range
$16.3M / $25.1M
FY2018-FY2022
Trend
-35.2%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $25M to $16M over the past 2 years.
Based on SEC 10-K filings.
$16M in FY2022 with a 3-year CAGR of +22.4%.
Improved from $25M to $16M over the past 2 years.
Total Debt over time
Growth rates
- 3-Year CAGR
- +22.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +22.4%, indicating consistent growth.
- In FY2022, total debt decreased 35.2% year-over-year.
- Peak total debt was recorded in FY2021.
- Lowest total debt in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -3.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $16.3M | -35.2% |
| FY2021 | $25.1M | +2.3% |
| FY2020 | $24.5M | +176.5% |
| FY2019 | $8.9M | -11.2% |
| FY2018 | $10.0M | - |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026